Peroxisome proliferator‐activated receptor‐δ induces insulin‐induced gene‐1 and suppresses hepatic lipogenesis in obese diabetic mice

Xiaomei Qin, Xuefen Xie, Yanbo Fan, Jianwei Tian, Youfei Guan, Xian Wang, Yi Zhu, Nanping Wang – 24 March 2008 – Primary nonalcoholic fatty liver disease is one of the most common forms of chronic liver diseases and is associated with insulin‐resistant states such as diabetes and obesity. Recent work has revealed potential implications of peroxisome proliferator‐activated receptor‐δ (PPARδ) in lipid homeostasis and insulin resistance.

Robust antiviral activity of R1626, a novel nucleoside analog: A randomized, placebo‐controlled study in patients with chronic hepatitis C

Stuart K. Roberts, Graham Cooksley, Gregory J. Dore, Richard Robson, David Shaw, Heather Berns, George Hill, Klaus Klumpp, Isabel Najera, Carla Washington – 18 March 2008 – The nucleoside analog R1479 is a potent and highly selective inhibitor of nonstructural protein 5B–directed hepatitis C virus (HCV) replication in vitro. R1626, a tri‐isobutyl ester prodrug of R1479, was developed to increase bioavailability and improve antiviral activity.

Subscribe to